<DOC>
	<DOCNO>NCT01436071</DOCNO>
	<brief_summary>A randomised , double-blind , placebo-controlled ( rescue medication ) , multi-centre study evaluate efficacy safety inhale fluticasone furoate treatment persistent asthma adult adolescent currently receive inhale corticosteroid</brief_summary>
	<brief_title>Clinical Study Evaluating Safety Efficacy Fluticasone Furoate People With Asthma</brief_title>
	<detailed_description>This multi-centre , randomise , placebo control ( rescue medication ) , double-blind , parallel group study . Subjects meet inclusion criterion none exclusion criterion Visit 1 ( Screening Visit ) enter two week Run-in Period . Subjects fail screen eligible re-screening . During run-in double-blind treatment period subject maintain electronic daily diary record morning even peak expiratory flow ( PEF ) , asthma symptom score rescue albuterol/salbutamol use . At Visit 2 ( end run-in/Randomisation Visit ) , subject meet eligibility criterion randomise either inhaled Fluticasone Furoate 50 mcg inhale placebo . In addition subject supply albuterol/salbutamol inhalation aerosol use require treat symptom . Subjects attend 4 on-treatment visit Visits 3 , 4 , 5 , 6 ( Weeks 2 , 4 , 8 12 respectively ) . Subjects receive treatment 84 day ( 12 week ) . A follow-up contact perform 1-week completing study medication ( Visit 7 ) . Subjects participate study maximum 15 week ( include screening , treatment follow-up contact ) .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Signed informed consent Outpatient least 12 year age diagnosis asthma least 12 week first visit Both gender ; female child bear potential must willing use appropriate contraception study Prebronchodilator FEV1 least 60 % predict FEV1 reversibility least 12 % 200mls Current asthma therapy include noncorticosteroid controller and/or shortacting beta agonist History lifethreatening asthma exacerbation within past 10 year Asthma exacerbation require treatment oral corticosteroid within last 3 month require overnight hospital stay within 6 month Current recent respiratory infection current oral candida infection Presence another significant respiratory disease medical condition control could affect subject safety study outcome Known suspect allergy study drug material Taking another investigational medication prohibit medication study Previous treatment inhale fluticasone furoate phase II III study Current smoker former smoker significant tobacco exposure Children Care</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>